OncoC4 Secures $50 Million Series B Funding to Advance Immuno-Oncology Pipeline
核心洞察
OncoC4 (搜索) closed a nearly $50 million Series B financing round led by GBA Fund (搜索) to support clinical development of its immuno-oncology pipeline.
The clinical-stage biotechnology company was founded in 2020 by renowned immunologists Dr. Yang Liu and Dr. Pan Zheng with expertise in translational medicine.
The company's pipeline features innovative therapies with first-in-class or best-in-class potential targeting cancer (搜索) and neurodegenerative diseases.
OncoC4 (搜索), a clinical-stage biotechnology company based in Rockville, Maryland, announced the closing of a Series B financing round totaling nearly $50 million. The funding round was led by GBA Fund (搜索), with additional participation from the company's co-founders and existing investors including HM Capital (搜索), 3E Bioventures Capital (搜索), and Kaitai Capital (搜索).
Company Foundation and Leadership
Founded in 2020 by two renowned immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng, OncoC4 (搜索) has leveraged deep expertise in immuno-oncology and translational medicine to build its therapeutic pipeline. Dr. Yang Liu serves as Co-Founder, Chairman of the Board, CEO, and Chief Scientific Officer of the company.
"Our Series B financing round progressed rapidly, and we deeply appreciate our investors' recognition of our Company and continual support," said Dr. Liu. "We are committed to rigorously advancing the global development of our core pipeline, while strategically expanding business development activities, with the ultimate goal of delivering more disruptive therapies to patients worldwide."
Pipeline and Therapeutic Focus
OncoC4 (搜索) is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer (搜索) and neurodegenerative diseases. The company's pipeline features assets with first-in-class and best-in-class potential, targeting both novel and well-validated targets across oncology and immunological diseases.
Funding Utilization
The proceeds from the Series B financing will primarily be used to support the advancement of clinical development of the company's pipeline programs. The funding will also enable strategic expansion of business development activities as OncoC4 (搜索) works toward delivering innovative therapies to patients worldwide.
The successful completion of this financing round demonstrates investor confidence in OncoC4 (搜索)'s approach to developing innovative biologics and positions the company to advance its clinical programs in the competitive immuno-oncology landscape.